Tresiba (insulin degludec) is a prescription drug that’s used to manage high blood sugar in people with diabetes. Tresiba’s cost may depend on your dosage, your health insurance, and the pharmacy you ...

BARCELONA, Spain, Sept. 19, 2019 /PRNewswire/ -- According to new data from the CONCLUDE head-to-head trial, Tresiba ® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a ...

CVS Health (CVS) has reached a settlement with the U.S. government, requiring the company to pay $37.76M to resolve claims ...

BARCELONA—Novo Nordisk’s Tresiba is battling it out with Sanofi’s Toujeo in the next-gen insulin category. And while the Danish drugmaker had been hoping to show its contender could top Sanofi’s rival ...

SAN FRANCISCO—Sanofi’s Toujeo has been battling it out against Novo Nordisk’s Tresiba in the next-generation basal insulin market, but new data could give it an edge in one key pool of diabetes ...

Please provide your email address to receive an email when new articles are posted on . O’Brien: An initial response is to consider the individual’s insurance formulary. However, when an insurance ...

Novo Nordisk, a global healthcare company, has launched Tresiba (insulin degludec) in Denmark for people with type 1 and type 2 diabetes. Tresiba is indicated for the treatment of diabetes mellitus in ...

Please provide your email address to receive an email when new articles are posted on . Novo Nordisk announced a voluntary recall of select insulin product samples that were stored at temperatures ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...